

# PLASMA VOLUME MARKER QUANTIFICATION WORKING GROUP

# **Terms of Reference**

The WADA Plasma Volume Marker Quantification Working Group (PV Quantification WG) is a specific Working Group<sup>1</sup> created by WADA Management.

These Terms of Reference (ToR) are approved by the WADA Director General, following consultation with the responsible Director in charge of the Group and the Chair of the WADA Laboratory Expert Advisory Group (Lab EAG).

#### **Purpose**

Plasma volume (PV) fluctuations have a significant impact on the interpretation of hematological Passports. A panel of PV markers has been developed and validated that can be used to correct for fluctuations in PV in the ABP and has been approved by the WADA Hematological ABP Working Group for implementation.

Based on a recommendation from the WADA Hematological ABP WG, the PV Quantification WG will provide recommendations for harmonization of the analytical strategy for the quantification of PV markers in WADA accredited Laboratories.

The PV Quantification WG will carry out its mandate over the February to December 2023 period. It will deliver recommendations to WADA on an ongoing basis during this period. The necessary meeting timelines will be framed with this in mind.

#### **Objectives/Key Activities**

The PV Quantification WG will:

- 1) Identify possible analytical strategies for the harmonized and cost-effective quantification of PV markers for the purposes of the ABP.
- 2) Carry out a thorough analysis of the pros and cons of each potential analytical approach.
- 3) Provide a recommendation for the optimal analytical strategy for the measurement of PV markers for the purposes of the ABP.

<sup>&</sup>lt;sup>1</sup> WGs are created on an as-needed basis only, and generally with a defined mandate requiring deliverables within a set timeframe. Where the expected deliverables are not met, an extension of mandate is possible, however it is not expected that WGs continue indefinitely. If it is considered that their work should be ongoing in nature, whether WG should be elevated to an Expert Advisory Group would need to be determined.



- 4) Define specific requirements for suitable internal and external quality controls for such an approach.
- 5) Provide recommendations for adaptation of existing International Standards and/or Technical Documents, or develop new regulation (i.e. new Technical Document or Laboratory Guidelines) if needed, for the quantification of PV markers for the ABP; and
- 6) Advise WADA on the implementation phase of this tool to ensure reliable use among antidoping partners including WADA accredited Laboratories and Anti-Doping Organizations.

#### **Reporting Structure**

The PV Quantification WG reports to WADA Management and will provide its final report to the WADA Lab EAG.

# Membership/Composition

The composition of the PV Quantification WG shall not exceed a maximum of 8-10 members however an exception may be applied if deemed necessary.

The WADA Director General, following consultation with the responsible Director in charge of PV Quantification WG and the Chair of the WADA Lab EAG will appoint members to the PV Quantification WG.

Members are selected on the basis of their relevant background and experience (e.g. expertise in the use of the ABP, the fields of clinical and laboratory hematology, clinical chemistry, and laboratory analysis).

The Members of the PV Quantification WG are recorded on the WADA website.

If required, additional experts may be called upon on an ad-hoc basis for their contributions.

#### Chair/Rapporteur

The PV Quantification WG Chair<sup>2</sup> is selected based on their proven record and expertise in the use of the ABP, the fields of clinical and laboratory hematology, clinical chemistry, and laboratory analysis.

He/she shall act as the official Rapporteur who is responsible for ensuring appropriate coordination with WADA Management, delivering the final report to the Chair of the WADA Lab EAG and for providing accurate and timely information on all relevant issues.

# **WADA Liaison**

The WADA Science and Medicine Department, and in particular the Associate Director ABP, will serve as the primary liaison between WADA and the PV Quantification WG.

<sup>&</sup>lt;sup>2</sup> There are occasions where WADA staff may chair a WG, e.g. when an external chair is not deemed to be practical.



The Associate Director ABP will be an observer<sup>3</sup> to the PV Quantification WG in the sense that they contribute to and bring expertise to support the work of the PV Quantification WG but does not have a voting position. Additional WADA Science and Medicine Department staff may also participate in PV Quantification WG meetings as WADA experts on particular subject matters and to provide general support to the group where required.

# **Meetings and Working Norms**

The objective of the PV Quantification WG is to deliver their final report to WADA by 31 December 2023. The PV Quantification WG carry out its work virtually via video or teleconference (as determined by WADA) as many times as is necessary to complete its mandate.

The PV Quantification WG normally operates on the basis of consensus and maintains as informal a manner as is possible or appropriate for the conduct of business. Consensus will be sought whenever possible. In the event of divergence of opinion or disagreement concerning recommendations, the absolute majority (determined by vote by hand) will rule. In the event of a tie, the Chair has the casting vote. There is presently no formal practice concerning a quorum. The Chair has the responsibility to determine if a quorum is present. Meeting notes will record any dissenting opinion on request.

The Chair may limit discussion of resurfacing issues by referring to previous recommendations or conclusions of previous discussions.

Meeting notes of the PV Quantification WG meetings, reports and correspondence relative to the group's work shall be retained at the WADA Headquarters.

# **Conflict of Interest**

PV Quantification WG members will be bound by the Conflict of Interest policy. They will be required to annually complete and sign a Statement of Absence of Conflict of Interest in accordance with the policy.

#### Confidentiality

All group members are required to sign a Confidentiality Agreement upon appointment (and again at the start of each year if their appointment is renewed). This ensures all members reflect on the confidential nature of their WADA work and confirm their adherence to such confidentiality rules.

# **Communications and Media**

All PV Quantification WG members must read and comply with WADA's Media Relations policy. If a member should receive a request for an interview in relation to their role in WADA or WADA's work they should first consult with the WADA Head of Media Relations or (if absent), with the WADA Communications Director.

#### **Budget and Financial Support**

WADA shall provide the necessary administrative and operational resources for meetings.

<sup>&</sup>lt;sup>3</sup> Unless they are appointed as the Chair of the WG.



Where meetings are held virtually and meet certain rules such as a minimum duration, a daily indemnity for virtual attendance is disbursed.

It is acknowledged that some experts go above and beyond, including providing extensive advice throughout the year, outside of annual meetings. WADA offers a further daily indemnity to experts for such work carried out. The specific indemnity details are outlined in the "Overview of WADA Working Groups" document provided to Members on appointment.

# **Effective Date**

These ToR came into effect in February 2023 and are published on the WADA website.